短葶藶鹼市場規模、佔有率和成長分析：按劑型、適應症、療法、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球短葶藶市場價值 4.873 億美元，預計到 2025 年將成長至 5.2044 億美元，到 2033 年將成長至 8.8093 億美元，在預測期（2026-2033 年）內複合年成長率為 6.8%。

從短葶飛蓬（Erigeron breviscapus）中提取的短葶飛蓬鹼（breviscapine）正迅速崛起為專注於腦血管保護和微循環改善的醫藥市場中的關鍵成分。缺血性中風及相關神經血管疾病的發生率不斷上升，尤其是在亞洲和歐洲老化社會，這推動了對有效且實證治療的需求。短葶飛蓬鹼最初作為傳統中藥使用，如今已獲得多個國家的監管部門批准，並拓展了其在循環系統和周邊動脈疾病的臨床應用，從而獲得了國際認可。多中心研究的積極結果促成了醫保報銷、醫院採購量的增加以及生產商產量的提高。人工智慧驅動的藥物研發的引入，透過最佳化研發流程和支持創新型短葶飛蓬鹼製劑的推出，進一步推動了市場變革，吸引了眾多投資者對這一高成長細分市場的濃厚興趣。

全球短葶藶市場成長要素

全球布雷維卡平市場正經歷顯著成長，主要驅動力在於其公認的神經保護作用以及作為輔助療法的臨床應用日益廣泛。隨著中風及相關血管疾病發生率的上升，臨床醫師擴大開立布雷維卡平處方，醫療機構和專科藥局的需求也隨之激增。這種臨床支持不僅增強了醫生的信心，也促進了布雷維卡平更廣泛地納入治療指南，並鼓勵製藥公司提升產能。此外，倡導團體也積極宣傳替代療法，這有助於提升布雷維卡平在治療過程中的重要性。因此，市場勢頭依然強勁，並將推動長期成長。

全球短葶藶市場的限制因素

全球布雷維卡平市場面臨許多挑戰，主要源自於歐洲和北美監管機構的嚴格監管要求。這些機構通常要求提供超越現有研究成果的全面臨床證據，導致核准流程延長，並增加潛在投資者的不確定性。這種謹慎的監管方式會阻礙新進業者進入市場，促使製藥公司將資源集中在監管路徑更為清晰的替代化合物。因此，布雷維卡平產品的商業化進程被延緩，阻礙了整體市場成長。此外，缺乏標準化的區域性指南也進一步加劇了生產商合規的難度。

全球短葶藶市場趨勢

受全球傳統中醫藥（TCM）接受度不斷提高的推動，布雷維卡平的全球市場呈現顯著成長。隨著醫療專業人員日益認可其血管擴張和神經保護作用，布雷維卡平已被納入多成分中藥製劑和聯合治療中。製藥公司與中藥生產商之間的合作正在推動布雷維卡平萃取物的標準化，從而提升市場上的品質和可靠性。隨著消費者越來越傾向選擇天然植物來源療法以輔助傳統醫學，布雷維卡平的通路也不斷拓展，尤其是在亞洲和新興市場，這進一步鞏固了布雷維卡平在現代醫療保健領域的地位。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球短葎草素市場規模：以劑型分類

• 注射藥物
• 藥片
• 膠囊
• 其他

全球短葶藶鹼市場規模：依適應症分類

• 缺血性中風
• 心臟疾病
• 糖尿病微血管病變
• 其他

全球短葶藶鹼市場規模：依治療類型分類

• 單藥治療
• 聯合治療
• 其他

全球短葶花市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

全球短葶花市場規模：依最終用戶分類

• 醫院
• 專科診所
• 居家照護
• 其他

全球短葶藶市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Yunnan Baiyao Group Co., Ltd.
• Kunming Pharmaceutical Corporation
• Harbin Medisan Pharmaceutical Co., Ltd.
• Shijiazhuang Yiling Pharmaceutical Co., Ltd.
• Livzon Pharmaceutical Group Inc.
• Shandong Luye Pharmaceutical Co., Ltd.
• Guangxi Wuzhou Pharmaceutical Group Co., Ltd.
• Guizhou Bailing Group Pharmaceutical Co., Ltd.
• Tasly Pharmaceutical Group Co., Ltd.
• Hunan Fangsheng Pharmaceutical Co., Ltd.
• Sichuan Kelun Pharmaceutical Co., Ltd.
• Jilin Aodong Pharmaceutical Group Co., Ltd.
• Harbin Pharmaceutical Group Co., Ltd.
• China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
• Tonghua Dongbao Pharmaceutical Co., Ltd.
• Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
• Zhejiang Conba Pharmaceutical Co., Ltd.
• Shandong Buchang Pharmaceuticals Co., Ltd.
• Jiangsu Kanion Pharmaceutical Co., Ltd.
• Tianjin Tasly Group

結論與建議

Global Breviscapine Market size was valued at USD 487.3 Million in 2024 and is poised to grow from USD 520.44 Million in 2025 to USD 880.93 Million by 2033, growing at a CAGR of 6.8% during the forecast period (2026-2033).

Breviscapine, an extract from Erigeron breviscapus, is emerging as a pivotal player in the pharmaceutical market focused on cerebrovascular protection and microcirculation improvement. The increasing incidence of ischemic stroke and related neurovascular disorders, particularly among aging populations in Asia and Europe, is driving the demand for effective, evidence-based therapies. Initially utilized in traditional Chinese medicine, breviscapine has gained international recognition through regulatory approvals in several countries, expanding its clinical applications into cardiology and peripheral artery disease. Positive results from multi-center studies have prompted health insurance reimbursements, enhancing hospital procurement and encouraging manufacturers to increase production. The integration of AI-driven drug discovery is further transforming the market by optimizing development processes and supporting the introduction of innovative breviscapine formulations, attracting significant investor interest in this high-growth niche.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Breviscapine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Breviscapine Market Segments Analysis

Global breviscapine market is segmented by dosage form, indication, therapy type, distribution channel, end user and region. Based on dosage form, the market is segmented into Injection, Tablets, Capsules and Others. Based on indication, the market is segmented into Ischemic Stroke, Coronary Heart Disease, Diabetic Microvascular Disease and Others. Based on therapy type, the market is segmented into Monotherapy, Combination Therapy and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Breviscapine Market

The global breviscapine market is experiencing significant growth, largely driven by its recognized neuroprotective properties and increasing clinical use as a therapeutic adjunct. As clinicians increasingly prescribe breviscapine in response to the rising prevalence of stroke and related vascular disorders, demand is surging within healthcare facilities and specialty pharmacies. This clinical support not only boosts physician confidence but also encourages wider integration into treatment guidelines, prompting pharmaceutical companies to enhance their production capabilities. Furthermore, advocacy groups are actively raising awareness of alternative therapies, which helps position breviscapine more prominently within care pathways, thereby maintaining strong market momentum and fostering long-term growth.

Restraints in the Global Breviscapine Market

The global breviscapine market faces significant challenges primarily due to stringent regulatory requirements imposed by various authorities in Europe and North America. These bodies often require comprehensive clinical evidence that surpasses the current research available for breviscapine, leading to prolonged approval processes and increased uncertainty for potential investors. This cautious regulatory approach can deter new participants from entering the market, prompting pharmaceutical companies to invest their resources in alternative compounds with more clear-cut regulatory pathways. As a result, the commercialization of breviscapine products is slowed down, hampering overall market growth. Additionally, the absence of standardized guidelines across different regions further complicates compliance for manufacturers.

Market Trends of the Global Breviscapine Market

The Global Breviscapine market is witnessing a significant upward trend driven by the rising acceptance of traditional Chinese medicine (TCM) on a global scale. This surge is leading to its integration into multi-component herbal formulations and combination therapies, as practitioners increasingly recognize its vasodilatory and neuroprotective capabilities. Collaborations between pharmaceutical companies and TCM manufacturers are fostering the standardization of breviscapine extracts, enhancing quality and credibility within the market. As consumers show a growing preference for natural, plant-based therapeutics that complement conventional medicine, the distribution channels are expanding, particularly across Asia and emerging markets, solidifying breviscapine's position in modern healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Breviscapine Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Injection
• Tablets
• Capsules
• Others

Global Breviscapine Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Ischemic Stroke
• Coronary Heart Disease
• Diabetic Microvascular Disease
• Others

Global Breviscapine Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Monotherapy
• Combination Therapy
• Others

Global Breviscapine Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Breviscapine Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Breviscapine Market Size & CAGR (2026-2033)

• North America (Dosage Form, Indication, Therapy Type, Distribution Channel, End User)
  • US
  • Canada
• Europe (Dosage Form, Indication, Therapy Type, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Dosage Form, Indication, Therapy Type, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Dosage Form, Indication, Therapy Type, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Dosage Form, Indication, Therapy Type, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Yunnan Baiyao Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kunming Pharmaceutical Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harbin Medisan Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Livzon Pharmaceutical Group Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shandong Luye Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangxi Wuzhou Pharmaceutical Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guizhou Bailing Group Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tasly Pharmaceutical Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hunan Fangsheng Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sichuan Kelun Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jilin Aodong Pharmaceutical Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harbin Pharmaceutical Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang Conba Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shandong Buchang Pharmaceuticals Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Kanion Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tianjin Tasly Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations